Bausch Health Companies Inc. (BHC) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Q2 2026
EPS
$1.26
est $1.01
+25.1%
Revenue
$2.85B
est $2.66B
+7.3%
Bausch Health smashed Q2 expectations with adjusted EPS of $1.26, blowing past consensus by 25%, as its blockbuster Xifaxan drug rocketed 26% higher to fuel a 21% surge in the Salix segment. The healthcare conglomerate hiked full-year guidance and nearly doubled operating cash flow while paring back its towering debt load, though it flagged 2027 risks from CMS-negotiated pricing on Xifaxan and lingering tariff uncertainty.
Mentioned: BHC